April 26, 2019 / 12:27 PM / 3 months ago

BRIEF-Forty Seven Inc Expands Collaboration With Genentech To Include Third Clinical Trial In Non-Hodgkin’S Lymphoma

April 26 (Reuters) - Forty Seven Inc:

* FORTY SEVEN INC. EXPANDS COLLABORATION WITH GENENTECH TO INCLUDE THIRD CLINICAL TRIAL IN NON-HODGKIN’S LYMPHOMA

* FORTY SEVEN - THIRD CLINICAL TRIAL, EVALUATING CO’S CD47 ANTIBODY 5F9 WITH GENENTECH’S ANTI-CD20 ANTIBODY RITUXIMAB & ANTI-PDL1 ANTIBODY, ATEZOLIZUMAB

* FORTY SEVEN INC - EXPECTS TO REPORT UPDATED DATA FROM PHASE 2 STUDY IN Q2 OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below